Hypoglycemia

Hypoglycemia — abnormally low blood glucose — is the single most common acute complication of diabetes pharmacotherapy, and among the most frequent reasons a person with diabetes contacts, or is counseled by, a pharmacist. It is overwhelmingly a complication of the drugs used to treat diabetes rather than of diabetes itself: insulin and the insulin secretagogues — sulfonylureas foremost — cause the large majority of clinically significant episodes, since both raise circulating insulin independent of the glucose-sensing feedback a non-diabetic pancreas normally provides.^[1]

This chapter is deliberately a companion to, not a restatement of, the Diabetes Mellitus and Diabetes Mellitus — Chronic Complications chapters, which cover diagnosis, glycemic targets, and the full drug-selection algorithm for diabetes itself; that foundation is assumed here. Hypoglycemia earns its own chapter because it is acute, genuinely dangerous, and among the things a pharmacist is asked to manage most directly — reviewing a new sulfonylurea or insulin prescription, dispensing a glucagon product, or fielding a patient's own account of a "low." This chapter goes deeper than a companion chapter's brief overview on exactly the 3 points that matter most at the counter: the full severity classification, the glucagon rescue protocol in real counseling detail, and Canadian driving-safety counseling.

Diabetes Canada, adopting the International Hypoglycemia Study Group framework, defines hypoglycemia operationally rather than by a single number alone: symptoms consistent with hypoglycemia, a measured plasma glucose low enough to explain them (below 4.0 mmol/L in a person treated with insulin or an insulin secretagogue), and resolution of the symptoms once glucose is corrected — a pattern classically known as Whipple's triad, borrowed from the older insulinoma literature and still the practical bedside standard for confirming that "feeling low" really is hypoglycemia.^[1]

Severity — the classification that actually drives management

Diabetes Canada classifies hypoglycemia into 3 severities, and this classification — not the glucose number alone — is what determines whether a person can safely treat themselves:

Mild and moderate hypoglycemia are both self-treatable — the feature that actually changes management is whether the person can safely swallow and treat themselves, not the exact symptom mix. This mild/moderate/severe framework maps onto the numeric International Hypoglycemia Study Group Level 1 (glucose 3.0-3.9 mmol/L)/Level 2 (glucose below 3.0 mmol/L)/Level 3 (severity-defined, at any glucose) terminology used in the companion Diabetes Mellitus chapter's own hypoglycemia algorithm — the 2 systems describe the same clinical reality from slightly different angles, and Diabetes Canada's 2023 update explicitly aligns them.^[1]

Symptom pattern — adrenergic first, neuroglycopenic as glucose falls further

Symptoms progress in a genuinely teachable pattern. Adrenergic (autonomic) symptoms — tremor, sweating, palpitations, hunger, anxiety — typically appear first as glucose begins to fall, generated by the counter-regulatory catecholamine surge itself rather than by brain glucose deprivation, and are what most people learn to recognize as their own personal warning signs.^[1] As glucose falls further, neuroglycopenic symptoms appear, reflecting the brain's own fuel shortage rather than a hormonal reflex: executive function (insight, judgment, calculation, speech, memory) is typically the first cognitive domain affected, followed by stupor — confusion, slurred speech, slow reaction times, poor coordination — and, if glucose continues to fall, seizure, loss of consciousness, and potentially brain damage or death.^[2]

Hypoglycemia unawareness

Hypoglycemia unawareness occurs when the threshold for the adrenergic warning symptoms is close to, or lower than, the threshold for neuroglycopenic symptoms, such that the first sign of hypoglycemia is confusion or loss of consciousness, with no useful preceding warning at all.^[1] The mechanism is a genuinely important counseling point: frequent hypoglycemia itself blunts the adrenergic warning response (defective glucose counter-regulation), so each low episode raises the risk that the next one goes unrecognized until it is severe — a vicious cycle that is exactly why recurrent hypoglycemia matters beyond any single episode.^[1]

The genuinely good news: hypoglycemia unawareness is often reversible. Strict avoidance of any further hypoglycemia for as little as 2 days, and more reliably over a period of up to about 3 months, has been associated with improved recognition of warning symptoms in many patients — the clinical rationale for deliberately relaxing glycemic targets in a patient with recurrent lows rather than simply treating each episode in isolation.^[1]

Complications of severe or recurrent hypoglycemia

Beyond the immediate episode, hypoglycemia carries real downstream risk: injury from a fall or a motor vehicle crash during a neuroglycopenic episode, seizure, and — rare with prompt treatment, but real — coma, permanent neurologic injury, or death.^[2] Recurrent hypoglycemia is itself a complication generator: each episode raises the risk of hypoglycemia unawareness, and a well-documented psychological complication, fear of hypoglycemia, leads some patients to deliberately run their glucose higher than target to avoid another low — trading a real but often overweighted short-term risk for the genuine longer-term risk of undertreated hyperglycemia. Ask about this directly; it is easy to miss in a routine visit.^[1]

Type 1 diabetes

• A prior severe hypoglycemic episode — the single strongest predictor of another.^[1]
• A1c below 6.0% — tight control itself raises risk.^[1]
• Hypoglycemia unawareness.^[1]
• Long insulin therapy duration.^[1]
• Autonomic neuropathy — blunts the counter-regulatory response.^[1]
• Adolescence.^[1]
• Preschool-aged children, who are unable to reliably self-detect or self-treat.^[1]

Type 2 diabetes

• Advancing age.^[1]
• Severe cognitive impairment.^[1]
• Poor health literacy.^[1]
• Food insecurity — genuinely important, and easy to overlook in a routine medication review.^[1]
• Hypoglycemia unawareness.^[1]
• Prolonged insulin therapy.^[1]
• Renal impairment — reduces clearance of insulin and, particularly, of renally-cleared sulfonylureas and their active metabolites, prolonging and intensifying their glucose-lowering effect.^[1]
• Peripheral or autonomic neuropathy.^[1]

Situational and behavioural

• Skipped, delayed, or smaller-than-usual meals relative to the insulin or secretagogue dose already taken.
• Exercise without a corresponding dose or carbohydrate adjustment — risk can persist for several hours after the activity ends, including overnight.
• Alcohol — blunts hepatic gluconeogenesis and reduces the sympathoadrenal counter-regulatory response; risk can extend well beyond the drinking episode itself, and alcohol intoxication can itself mask the warning symptoms.^[1]
• Sleep — the sympathoadrenal warning response is itself blunted during sleep, so nocturnal hypoglycemia is disproportionately likely to go unrecognized until it is severe.^[1]

Medication-related

• Insulin and the insulin secretagogues (sulfonylureas, meglitinides) are the major pharmacologic causes. Other antihyperglycemic classes — metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, thiazolidinediones — carry low or negligible hypoglycemia risk alone but potentiate insulin/secretagogue-induced hypoglycemia when combined; see Diabetes Mellitus for the complete drug-selection algorithm.
• Within the sulfonylurea class specifically, glyburide carries a materially higher hypoglycemia risk than gliclazide or glimepiride, particularly in older adults and renal impairment — see Diabetes Mellitus.
• Dose confusion and administration errors — the wrong insulin product or pen, unit/mL mix-ups, or double-dosing after uncertainty about a missed dose — are a genuinely common, pharmacist-preventable cause; medication reconciliation and clear labelling matter here as much as pharmacology does.
• Interacting drugs that potentiate a sulfonylurea's hypoglycemic effect — salicylates, sulfonamides, and MAO inhibitors increase it directly; beta-blockers do not potentiate the hypoglycemic effect itself but blunt or mask the adrenergic warning symptoms, delaying recognition — see Diabetes Mellitus for the complete interaction table.

Point-of-care confirmation

Confirm hypoglycemia with a point-of-care capillary glucose measurement whenever possible before treating — both to confirm the diagnosis and to have a baseline to recheck against. In a clearly symptomatic, at-risk patient with no meter immediately available, treat first rather than delaying treatment to find one.

Whipple's triad — the operational definition

Diabetes Canada's operational definition of hypoglycemia has 3 components, all of which should be present to confidently confirm the diagnosis: (1) autonomic or neuroglycopenic symptoms consistent with hypoglycemia; (2) a plasma glucose below 4.0 mmol/L in a person treated with insulin or an insulin secretagogue; and (3) resolution of the symptoms following carbohydrate administration.^[1] This 3-part pattern — symptoms, a corresponding low glucose, and resolution with correction — is the same logic classically known as Whipple's triad.

Severity at a glance

^[1]

Differential diagnosis

Consider other causes of the same symptom picture, especially without a clear insulin/secretagogue trigger: alcohol-related hypoglycemia, adrenal insufficiency, sepsis or critical illness, an insulinoma or other rare endogenous hyperinsulinism (Whipple's triad was originally described for exactly this scenario), and factitious or deliberate insulin/sulfonylurea misuse. Persistent or recurrent hypoglycemia with no clear medication explanation deserves specialist endocrine workup rather than repeated isolated treatment.

• Rapidly restore plasma glucose to a safe range and resolve symptoms — the immediate priority in every episode, regardless of severity.
• Avoid over-treatment — enough carbohydrate to correct the episode, not so much that it produces rebound hyperglycemia and, over repeated episodes, unwanted weight gain.^[1]
• Prevent recurrence — identify and address the actual precipitant (a missed meal, unadjusted exercise, alcohol, a dosing error, an interacting drug, a change in renal function) rather than treating each episode as an isolated event.
• Preserve or restore hypoglycemia awareness — relax glycemic targets and pursue a structured period of strict avoidance when unawareness is present, rather than accepting recurrent lows as an unavoidable cost of tight control.^[1]
• Equip the patient, and anyone at risk of severe hypoglycemia's household or regular caregivers, to recognize and treat every severity level confidently — including glucagon administration.^[1]
• Keep the patient safely and legally on the road where appropriate, by building the glucose-testing and reporting habits provincial licensing authorities require into routine self-management, rather than leaving driving safety as an afterthought.^[3]

Mild-to-moderate hypoglycemia — the "15-15 rule"

1st line give 15 g of fast-acting carbohydrate by mouth, preferably as glucose or sucrose tablets or a glucose solution rather than juice or glucose gel — tablets give a reliable, pre-measured dose, while juice is imprecise by portion size and gel works slowly and must be fully swallowed to reach the gut, so neither is preferred despite being common home go-tos.^[1]

Practical 15 g examples worth naming to a patient directly: 15 g glucose tablets (check the specific product's per-tablet gram content), 15 mL (3 teaspoons) or 3 packets of table sugar dissolved in water, 5 sugar cubes, 150 mL of regular (non-diet) juice or soft drink, 6 Life Savers candies (about 2.5 g of carbohydrate each), or 15 mL (1 tablespoon) of honey.^[1]

Retest and repeat recheck glucose 15 minutes after treatment; if it remains below 4.0 mmol/L, repeat another 15 g and recheck again in a further 15 minutes. This is the "15-15 rule" by name, and it is worth repeating to patients exactly this way — the instinct to eat a large amount all at once, or to stop as soon as symptoms ease without confirming glucose above 4.0 mmol/L, is common and works against a controlled, non-overshooting correction.^[1]

Follow with food once corrected, give the person's usual meal or snack due at that time of day; if the next meal is more than an hour away, give a snack that includes 15 g carbohydrate plus a protein source, to prevent glucose falling again before the next meal.^[1]

Avoid over-treatment resist the urge to keep eating past resolution "just in case" — over-treatment is a genuinely common, avoidable cause of rebound hyperglycemia and, over repeated episodes, unwanted weight gain.^[1]

Acarbose specifically a patient taking acarbose must use glucose (dextrose) tablets to treat hypoglycemia, or milk or honey if glucose is unavailable — acarbose blocks the enzymes that digest sucrose and more complex carbohydrates, so table sugar, most juices, and several other 15-15-rule foods will not work reliably in this specific patient.^[1]

Severe hypoglycemia, conscious and able to swallow safely

Treat with a larger oral dose 20 g of fast-acting carbohydrate, preferably glucose tablets or equivalent, then recheck glucose in 15 minutes and retreat with a further 15 g if it remains below 4.0 mmol/L — the same 15-15 pattern, started from a larger initial dose given the lower starting glucose.^[1]

Severe hypoglycemia, unable to swallow safely — glucagon is the critical rescue step

1st line, no IV access give glucagon 1 mg subcutaneously or intramuscularly. Glucagon mobilizes hepatic glycogen and produces a significant glucose rise (from roughly 3.0 to 12.0 mmol/L in one study) within about 60 minutes.^[1] Its effect is reduced in someone who has had more than 2 standard alcoholic drinks in the previous few hours, after prolonged fasting, or with advanced hepatic disease — all situations where hepatic glycogen stores are already depleted and glucagon has little substrate left to mobilize.^[1] Caregivers or support persons should call emergency services immediately when giving glucagon for severe hypoglycemia.^[1]

Traditional injectable glucagon emergency kits — a vial of lyophilized (freeze-dried) glucagon powder that a caregiver must reconstitute with a supplied diluent syringe immediately before use, then draw up and inject IM or SC — have a real, well-documented usability problem worth naming directly to patients and families, rather than assuming the kit alone is adequate preparation: in a simulated severe-hypoglycemia rescue, only 2 of 16 (13%) instructed caregivers successfully delivered a full, correct dose of injectable glucagon, and administration took roughly 2 minutes on average — long enough, under the stress of an actual emergency, for errors (wrong diluent volume, incomplete reconstitution, injecting air, hesitating over the injection itself) to occur.^[5]

Ready-to-use glucagon — nasal glucagon (a dry powder delivered into 1 nostril, absorbed through the nasal mucosa with no inhalation required, so it still works even if the person is not breathing normally) and prefilled subcutaneous glucagon products (a ready-to-inject syringe or auto-injector pen requiring no reconstitution) — have substantially simplified rescue administration. In the same simulation study, 15 of 16 (94%) caregivers correctly delivered a full dose of nasal glucagon, in about 16 seconds — roughly 7 times faster than the injectable kit — regardless of whether they had been specifically trained beforehand.^[5] A separate study of caregiver perceptions found nasal glucagon was rated easier to use, easier to prepare, and given with substantially more confidence than injectable glucagon among trained users (87.1% vs 54.8% rated it easy to use; 93.5% vs 54.8% felt confident using it correctly).^[6] An indirect comparison of the 3 ready-to-use products available — nasal glucagon, a prefilled glucagon injection, and dasiglucagon (a stabilized glucagon analogue delivered by prefilled auto-injector) — found all 3 achieved treatment success in over 98% of trial and real-world use, confirming the ready-to-use formulations are not just easier to administer but genuinely as effective as the traditional kit once successfully given.^[7]

Practical counseling point whichever formulation is prescribed, teach at least 1 household member or regular caregiver to recognize severe hypoglycemia and administer that specific product before it is ever needed, not at the moment of an emergency. If a household has struggled with, or expressed anxiety about, the reconstitution steps of a traditional kit, that is a legitimate, evidence-based reason to discuss switching to a ready-to-use formulation with the prescriber — not just a convenience preference.

Once the patient regains consciousness and can swallow safely, give oral fast-acting carbohydrate followed by a full meal or snack — glucagon's effect is transient, and glucose can fall again without a food follow-up, especially since the alcohol/fasting/hepatic-disease situations that blunt its effect are also the situations most likely to see a relapse.^[1]

In hospital, or wherever IV access is already available

IV dextrose for an unconscious patient with IV access already established — in hospital, in an ambulance, or at a supervised medical visit — give 10-25 g (20-50 mL of D50W) IV over 1-3 minutes as a faster, direct alternative to glucagon; unlike glucagon, it does not require time for hepatic glycogen mobilization to take effect.^[1]

Refractory or recurrent hypoglycemia after a sulfonylurea

Special situation, hospital-managed sulfonylurea-induced hypoglycemia (accidental overdose, renal impairment, or deliberate/pediatric ingestion) can be unusually prolonged and can recur repeatedly despite an initial dextrose bolus — because dextrose itself is a potent insulin secretagogue, repeated dextrose boluses alone can perpetuate a hypoglycemia-dextrose-more-insulin cycle rather than resolving it. Octreotide (a somatostatin analogue that directly suppresses insulin secretion) reduces the frequency of further hypoglycemic events and the number of additional dextrose boluses needed, and should be considered alongside dextrose — not as a substitute for it — for refractory sulfonylurea-induced hypoglycemia.^[4]